Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03715933 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
A Phase 1 study of Ewing Sarcoma, sponsored by Inhibrx Biosciences.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 321
- Enrollment target
- 20
- Study locations
NCT03715933 is a Phase 1 study of Ewing Sarcoma that is actively recruiting participants, run by Inhibrx Biosciences. The registered enrollment target is 321 participants, above the 97-participant average among 26 other Ewing Sarcoma trials with a reported enrollment target (231% higher). The trial reports 20 study locations across 12 states.
The verdict
NCT03715933, a Phase 1 study of Ewing Sarcoma, is actively recruiting participants, sponsored by Inhibrx Biosciences.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 321 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a first-in-human, open-label, non-randomized, three-part phase 1 trial of INBRX-109, which is a recombinant humanized tetravalent antibody targeting the human death receptor 5 (DR5).
Conditions Studied
Interventions
- DRUG Temozolomide
- DRUG Irinotecan
- DRUG carboplatin
- DRUG pemetrexed
- DRUG INBRX-109
Study Locations (20)
California
- Precision NextGen Oncology and Research - Beverly Hills
- City of Hope - Duarte
- Valkyrie Clinical Trials - Los Angeles
- University of California, San Diego (UCSD) - Moores Cancer Center - San Diego
- University of California, San Francisco (UCSF) - San Francisco
- Sarcoma Oncology Center - Santa Monica
Michigan
- University of Michigan - Ann Arbor
- START Midwest Michigan, PC - Grand Rapids
Pennsylvania
- Children's Hospital of Philadelphia- Center for Childhood Cancer Research - Philadelphia
- University of Pennsylvania Abramson Cancer Center - Philadelphia
Texas
- UT MD Anderson Cancer Center - Houston
- NEXT Oncology - San Antonio
Arizona
- HonorHealth Research Institute - Scottsdale
Colorado
- University of Colorado Hospital - Aurora
Georgia
- Emory University - Winship Cancer Institute - Atlanta
Illinois
- The University of Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 321 participants |
| Start Date | 2018-10-08 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03715933
The ClinicalTrials.gov registry entry for NCT03715933 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 321 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 97-participant average among 26 other Ewing Sarcoma trials with a reported enrollment target (231% higher). The listed sponsor is Inhibrx Biosciences, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ewing Sarcoma appearing as the primary indexed condition, and to 5 interventions - of which Temozolomide is the first listed.
NCT03715933 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Michigan, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03715933 about?
NCT03715933 is a clinical study titled "Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas". This is a first-in-human, open-label, non-randomized, three-part phase 1 trial of INBRX-109, which is a recombinant humanized tetravalent antibody targeting the human death receptor 5 (DR5).
What is the current status of trial NCT03715933?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 321 participants. The study started on 2018-10-08. Estimated completion is 2026-12.
What conditions does trial NCT03715933 study?
This clinical trial studies the following conditions: Ewing Sarcoma.
What interventions are being tested in trial NCT03715933?
The interventions under investigation include: Temozolomide (DRUG), Irinotecan (DRUG), carboplatin (DRUG), pemetrexed (DRUG), INBRX-109 (DRUG).
Who is sponsoring clinical trial NCT03715933?
This trial is sponsored by Inhibrx Biosciences, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03715933 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ewing Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
RECRUITING · Phase 1
-
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
RECRUITING · Phase 1
-
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
RECRUITING · Phase 1
-
Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants
RECRUITING · Phase 1
-
Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)
RECRUITING · Phase 1
-
Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.